ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 290

Viscosupplemenation Efficacy in Knee Oa Is Similar in Single-Injection Vs. Multi-Week Formulations and Across OA Severity and BMI Subgroups, but Better in Younger Patients

Thayer Mukherjee1, Fernando Bomfim2, Evan Wilder1, Lauren Browne2, Shira Aharon3, Kayleigh Toth1, Eric Strauss4 and Jonathan Samuels5, 1NYU Langone Medical Center, New York, NY, 2Rheumatology, NYU Langone Medical Center, New York, NY, 3NYU Langone Medical Center, Rheumatology, New York, NY, 4Orthopedic Surgery, NYU Langone Medical Center, New York, NY, 5Division of Rheumatology, Department of Medicine, NYU Langone Medical Center, New York, NY

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: hyaluronate, Knee, osteoarthritis and viscosupplementation

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2016

Session Title: Osteoarthritis – Clinical Aspects - Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Hyaluronic acid (HA) viscosupplementation is widely used in patients with knee osteoarthritis (KOA), but variable reported outcomes have impacted its incorporation into treatment algorithms.  The current study examined clinical predictors of response to HA injections.

Methods: Patients receiving HA injections during routine visits were enrolled if they had KOA pain for ≥1 month and VAS pain ≥30. Baseline assessments included BMI, the Knee Injury and Osteoarthritis Outcome Score (KOOS) questionnaire, and standing knee xrays scored for Kellgren-Lawrence grade. The use of single vs multi-week HA products, anatomic injection approach, and use of ultrasound guidance were additional variables.  Patients completed the KOOS at 2 months post-treatment to evaluate improvement from baseline.  

Results:   We screened 384 and enrolled 287 patients (65.5% female, age 62 years ±11, 28-88; BMI 31.0 kg/m2±6.7, 18-54) with a baseline mean KOOS pain score (0 to 100) of 51.5 ±17.4, We obtained 2 month follow-up from 226 patients, with a mean KOOS pain improvement of 9.6 (Fig. 1) and similar results with other KOOS subscores.             After 2 months, younger patients reported significantly better ΔKOOS pain improvement. Those <60 benefitted more than the 60-69 age group, with the mildest response from those 70 and older (11.9±16.7 vs 10.3±17.8 vs 4.8±14.4, p=0.042). A similar trend followed for the % of patients who showed any improvement in these subgroups (73.0%, 65.4%, 60.7%).             Patients with less severe radiographic disease trended towards more improvement, with KL0 vs KL1/2 vs KL3/4 ΔKOOS pain scores of 13.0±17.4, 11.7±17.7 and 7.9±16.0, p=0.205  and response rates of 76.9%, 71.9%, and 66.4%.             Those receiving a single-dose injection had similar ΔKOOS pain results than the traditionally-used multi-week versions (10.3±15.0 vs 9.2±17.5, p=0.674). This single-dose group displayed a higher % of any improvement (76.8% vs 63.1%).             Obese (BMI>30) and non-obese patients responded similarly with ΔKOOS pain averages of 10.2 and 8.9 and response rates of 68.7% and 65.8%. Further breakdown into smaller BMI subgroups was similarly unrevealing, as was a linear regression of BMI vs ΔKOOS Pain (R=0.178, p= 0.674). In addition, we found no significant difference in outcome from various anatomic needle approaches (medial, lateral, flexed knee) or from the use of ultrasound guidance.

Conclusion:  Younger KOA patients responded better 2 months following a course of HA viscosupplementation, and there was a trend towards more improvement in patients with less severe radiographic disease.  Obesity, anatomic approach and ultrasound guidance did not appear to impact response. Single-injection formulations provided as much improvement as multi-injection products by KOOS scores – with less time and expense. These results could tailor future algorithms for more appropriate and cost-effective use of HA in KOA management.

 


Disclosure: T. Mukherjee, None; F. Bomfim, None; E. Wilder, None; L. Browne, None; S. Aharon, None; K. Toth, None; E. Strauss, None; J. Samuels, None.

To cite this abstract in AMA style:

Mukherjee T, Bomfim F, Wilder E, Browne L, Aharon S, Toth K, Strauss E, Samuels J. Viscosupplemenation Efficacy in Knee Oa Is Similar in Single-Injection Vs. Multi-Week Formulations and Across OA Severity and BMI Subgroups, but Better in Younger Patients [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/viscosupplemenation-efficacy-in-knee-oa-is-similar-in-single-injection-vs-multi-week-formulations-and-across-oa-severity-and-bmi-subgroups-but-better-in-younger-patients/. Accessed January 27, 2023.
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/viscosupplemenation-efficacy-in-knee-oa-is-similar-in-single-injection-vs-multi-week-formulations-and-across-oa-severity-and-bmi-subgroups-but-better-in-younger-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences